Imara Inc
NASDAQ:IMRA
Intrinsic Value
Imara, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one IMRA stock under the Base Case scenario is 2.87 USD. Compared to the current market price of 21 USD, Imara Inc is Overvalued by 86%.
Valuation Backtest
Imara Inc
Run backtest to discover the historical profit from buying and selling IMRA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Imara Inc
Current Assets | 77.8m |
Cash & Short-Term Investments | 75.5m |
Other Current Assets | 2.2m |
Non-Current Assets | 5.5m |
PP&E | 1.5m |
Other Non-Current Assets | 4m |
Current Liabilities | 9.7m |
Accounts Payable | 3.4m |
Accrued Liabilities | 6.3m |
Non-Current Liabilities | 659k |
Other Non-Current Liabilities | 659k |
Earnings Waterfall
Imara Inc
Revenue
|
0
USD
|
Operating Expenses
|
-34.3m
USD
|
Operating Income
|
-34.3m
USD
|
Other Expenses
|
35.8m
USD
|
Net Income
|
1.5m
USD
|
Free Cash Flow Analysis
Imara Inc
IMRA Profitability Score
Profitability Due Diligence
Imara Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Imara Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
IMRA Solvency Score
Solvency Due Diligence
Imara Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Imara Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMRA Price Targets Summary
Imara Inc
Ownership
IMRA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IMRA Price
Imara Inc
Average Annual Return | -15.04% |
Standard Deviation of Annual Returns | 105.94% |
Max Drawdown | -98% |
Market Capitalization | 552m USD |
Shares Outstanding | 26 287 300 |
Percentage of Shares Shorted | 2.46% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Imara, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2020-03-12. The firm is engaged in developing and commercializing novel therapeutics to treat rare inherited genetic disorders of hemoglobin. The Company’s product pipeline includes IMR-687 (tovinontrine). IMR-687 is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD and beta-thalassemi. IMR-687 is a selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9), that has a multimodal mechanism of action that acts primarily on red blood cells (RBCs) and has the potential to act on white blood cells (WBCs), adhesion mediators and other cell types. PDE9 decreases cyclic guanosine monophosphate (cGMP), an active signaling molecule. The firm is conducting Phase II b clinical trials of IMR-68.
Contact
IPO
Employees
Officers
The intrinsic value of one IMRA stock under the Base Case scenario is 2.87 USD.
Compared to the current market price of 21 USD, Imara Inc is Overvalued by 86%.